Presentations, Posters & Abstracts

Oncotype DX™ Tools (RSPC)

Peer-reviewed Publication(s)
Risk of Recurrence and Chemotherapy Benefit for Patients With Node-Negative, Estrogen Receptor–Positive Breast Cancer: Recurrence Score Alone and Integrated With Pathologic and Clinical Factors
Tang G., Cuzick J., Costantino JP., Dowsett M., Forbes JF., Crager M., Mamounas EP., Shak S., and Wolmark N.
J Clin Oncol. 2011; 4365-4372.

Abstract #592
Using the 21-gene Recurrence Score and the recently developed Recurrence Score-Clinical-Pathologic to assess recurrence risk in patients with node-negative, ER-positive early-stage breast cancer receiving aromatase inhibitor treatment alone.
M. Crager, G. Tang, S. Shak; Genomic Health, Redwood City, CA; NSABBP Biostatistical Center and University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA
2011;

Abstract #S4-9
Comparing the prediction of chemotherapy benefit in patients with node-negative, ER-positive breast cancer using the recurrence score and a new measure that integrates clinical and pathologic factors with the recurrence score
Tang G, Costantino JP, Crager M, Shak S, Wolmark N. NSABP, Pittsburgh, PA, Genomic Health Inc., Redwood City, CA.
2010;

Abstract #509
Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach.
G. Tang, J. Cuzick, C. Wale, J. P. Costantino, M. Crager, S. Shak, N. Wolmark, M. Dowsett, J. F. Forbes; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Queen Mary, University of London, London, United Kingdom; Genomic Health, Redwood City, CA; National Surgical Adjuvant Breast and Bowel Project and Allegheny General Hospital, Pittsburgh, PA; The Royal Marsden Hospital, London, United Kingdom; University of Newcastle, Newcastle-upon-Tyne, United Kingdom
2010;

Top

2013 St. Gallen Breast Cancer Conference - St. Gallen, Switzerland

Abstract #P126
Review of traditional prognostic and predictive markers in early-stage breast cancer
Plun-Favreau J, Luthman S, C. Svedman C, et al.
2013;

Abstract #P138
Pooled analysis of 4 European studies assessing the impact of Oncotype DX on treatment decisions
Albanell J, Gligorov J, Holt S.D, et al.
2013;

Abstract #P141
Differences in Recurrence Score (RS) results between luminal A and luminal B breast cancer subtypes
Efrat N., Rizel S, Yerushalmi R, et al.
2013;

Abstract #P145
A comparison of risk classification as assessed by the MammaPrint and Oncotype DX assays
Svedman C, Clough K, Poulet B, et al.
2013;

Abstract #P146
The 21-gene breast cancer assay: summary of clinical evidence
Sing A.P., Baehner F.L., Yoshizawa C, et al.
2013;

Abstract #P147
The Oncotype DX DCIS Score and quantitative gene expression for ER, PR, and HER2: 1,071 patients
Tan V, Bailey H, Tsiatis A, et al.
2013;

Abstract #P148
The development of the DCIS Score: scaling and normalization in the Marin general population
Baehner F.L., Butler S.M., Yoshizawa C, et al.
2013;

Abstract #P154
Oncotype DX VS clinicopathologic factors in breast cancer: the experience from Greece and Cyprus
Nasioulas G, Kesisis G, Razi E, et al.
2013;

Abstract #P156
Impact of the Oncotype DX assay on decision-making in estrogen receptor positive early breast cancer
Jaafar H, Taher A, Quasmeh K, et al.
2013;

Abstract #P19
Quantitative gene expression by RT-PCR in special histologic subtypes of invasive breast cancer
Bailey V, Tsiatas A, Yoshizawa C, et al.
2013;

Abstract #P20
Quantitative gene expression by RT-PCR in classic and variant lobular carcinoma in ER+ breast cancer
Anderson J, Yoshizawa C, Watson D, et al.
2013;

Abstract #P200
Retrospective analysis of treatment decisions in patients with intermediate Recurrence Score results
Fried G
2013;

Abstract #P208
Budget impact analysis of the Oncotype DX Breast Cancer Test in France
Rouzier R, Laas E, Chéreau E, et al.
2013;

Abstract #P213
Recurrence Score fo prognosis and prediction of paclitaxel benefit in node(+)/ER(+) breast cancer
Mamounas E.P, Tang G., Paik S, et al.
2013;

Abstract #P281
Retropspective budget impact analysis on the use of Oncotype DX test in Ireland
Falahee M, Plun-Favreau J, Ercoli K.
2013;

Abstract #P283
Cost-effectiveness analysis of the 21-gene breast cancer test in Mexico
J. Bargallo Rocha F. Lara Medina, R. Shaw Dulin, V. Pérez Sánchez
2013;

Abstract #P284
Cost-effectiveness of Oncotype DX test vs current clinical practice: a Dutch cost perspective
Steuten R, Schutten M, Kip M, et al.
2013;

Abstract #P286
Economic impact of the Oncotype DX results guided adjuvant treatments in Turkey
Rózsa K, Horváth Z, Juhos É, et al.
2013;

Abstract #P287
Using the Recurrence Score in clinical practice: a HMO experience with a unified testing policy
Silverman N, Zick A, Beit-Or A, et al.
2013;

Abstract #P290
Family life during and after breast cancer treatment: A European patient survey
Mimoun D, Elia E, Braybrooke J, et al.
2013;

Top

2013 AUA − San Diego, CA

Abstract #2131
Development and validation of the biopsy‐based genomic prostate score (GPS) as a predictor of high grade or extracapsular prostate cancer to improve patient selection for active surveillance
Cooperberg M, Simko J, Falzarano S
2013;

Top

2013 ASCO - GI - San Francisco, CA

Abstract #349
Impact of the recurrence score (RS) result and mismatch repair status (MMR) on agreement between oncologists (MDs) for stage II colon cancer (CC) recurrence risk (RR) assessment: A novel clinical utility endpoint for prognostic markers
Kelley R. K., Lopatin M., Hwang J., et al.
2013;

Abstract #391
Real-world comparative economics of a 12-gene assay for prognosis in stage II colon cancer
Alberts S.R., Yu T., Behrens R.J., et al.
2013;

Abstract #453
Prospective evaluation of a 12-gene assay on treatment recommendations in patients with stage II colon cancer
Srivastava G, Renfro L. A., Behrens R. J.,et al.
2013;

Top

2013 ASCO - Chicago, IL

Abstract #5029
Evidence for a field effect in early prostate cancer (PCa): gene expression profiles in normal‐appearing prostate tissue (NT) adjacent to tumor (T) are predictive of clinical outcome.
Klein E, Maddala T, Lawrence J, Magi-Galluzzi C
2013;

Abstract #3640
Real-world comparative economics of a 12-gene assay for prognosis in stage II colon cancer
Yu T, Alberts S.R., Behrens R. J., et al.
2013;

Abstract #e14569
Impact of the Recurrence Score (RS) result and mismatch repair status (MMR) on agreement between oncologists (MDs) for stage II colon cancer (CC) recurrence risk (RR) assessment: A novel clinical utility endpoint for prognostic markers
Kelley R.K, Lopatin M, Hwang J, et al.
2013;

Abstract #e22111
Association of the colon cancer recurrence score with treatments received in patients with stage II colon cancer: The Clalit Health Services experience
Brenner B, Geva R, Beny A, et al.
2013;

Abstract #11018
Fusion transcript discovery in formalin-fixed paraffin-embedded human breast cancer tissues and its relation to tumor progression
Ma Y, Ambannavar R, Stephans J, et al.
2013;

Abstract #520
The relationship between quantitative HER2 gene expression by the 21-gene RT-PCR assay and adjuvant trastuzumab (H) benefit in NCCTG (Alliance) N9831
Perez E. A., Butler S. M., Dueck A. C, et al.
2013;

Abstract #560
Ethnic differences in tumor proliferation in women with early-stage breast cancer
Kalinsky K, Lim E.A., Andreopoulou E, et al.
2013;

Abstract #562
Phase II trial evaluating the use of 21-gene recurrence score (RS) to select preoperative therapy in hormone receptor (HR)-positive breast cancer
Zelnak A. B., Murali S, Styblo T. M., et al.
2013;

Abstract #565
Initial results from the 21-gene breast cancer assay registry: A prospective observational study in patients (pts) with ER+, early-stage invasive breast cancer (EBC)
Vacirca J.L, Tsai M. L., Brufsky A, et al.
2013;

Abstract #598
A comparative analysis of distant recurrence risk assessments by Oncotype DX recurrence score alone and integrated with clinicopathologic factors in early-stage breast cancer
Kelly C.M., Beamish R, McCaffrey J, et al.
2013;

Abstract #e11531
A retrospective study in the Spanish population with Oncotype dx recurrence score (RS) in breast cancer patients with positive and negative-lymph nodes
Estevez LG, Calvo I, Abad MF, et al.
2013;

Abstract #TPS655
ADAPT: Adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer
Harbeck N, Hofmann D, Gluz O, et al.
2013;

Top

2012 SABCS - San Antonio, TX

Abstract #OT3-3-02
ADAPT - Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer
Gluz O, Hofmann D, Kates RE, et al.
2012;

Abstract #P2-10-08
Prospective comparison of Recurrence Score and different definitions of luminal subtypes by central pathology assessment of single markers in early breast cancer: results from the Phase III WSG-planB Trial.
Gluz O, Kreipe HH, Kates RE, et al.
2012;

Abstract #P6-07-03
Risk classification of early stage breast cancer as assessed by MammaPrint and Oncotype DX genomic assays
Poulet B, Jamshidian F, Butler S, et al.
2012;

Abstract #P5-15-01
Cost-effectiveness of gene expression profiling for ductal carcinoma in-situ (Oncotype DCIS Score)
Alvarado MD, Harrison L, Solin LJ, Ozanne EM
2012;

Abstract #P5-15-06
Societal economics of the 21-gene Recurrence Score® in estrogen-receptor-positive early-stage breast cancer in Japan
Yamauchi H, Nakagawa C, Yamashige S, et al.
2012;

Abstract #S1-10
Association Between the 21-Gene Recurrence Score (RS) and Benefit from Adjuvant Paclitaxel in Node-positive, ER-positive Breast Cancer Patients (pts): Results from NSABP B-28
Mamounas EP, Tang G, Paik S, Baehner FL, et al.
2012;

Top

2012 ESMO - Vienna, Austria

Abstract #252
Meta-analysis of prospective European studies assessing the impact of using the 21-gene recurrence score assay on clinical decision making in women with ER-positive, HER2-negative early stage breast cancer
J. Albanell, S. Holt, J. Gligorov, W. Eiermann, C. Svedman
2012;

Abstract #289
Study of the impact of the 21-gene breast cancer assay on the use of adjuvant chemotherapy in women with breast cancer in a Mexican public hospital
J.E.R. Bargallo, F. Lara, R.J. Shaw Dulin, V. Perez-Sánchez, C. Villarreal-Garza, H. Maldonado-Martinez, A. Mohar-Betancourt, C. Yoshizawa, E. Burke, C. Chao
2012;

Top

2012 ASCO Breast Cancer Symposium - San Francisco, CA

Abstract #1
Prognostic impact of the 21-gene recurrence score (RS) on disease-free and overall survival of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28
Mamounas E, Tang G, Paik A, et al.
2012;

Abstract #190
The development of the DCIS score: Scaling and normalization in the Marin General Hospital cohort
Baehner F.
2012;

Top

2012 ASCO - GU - San Francisco, CA

Abstract # 21
Identification of Prostate Cancer-Expressed MicroRNAs Associated with Clinical Recurrence and Prostate Cancer Specific Survival Following Radical Prostatectomy
Klein E, Kiefer M, Crager M, Magi-Galluzzi C, Falzarano S, Pelham R, Cherbavaz D, Baker J, Shak S, Lee M
2012;

Top

2012 ASCO - GI - San Francisco, CA

Abstract #398
Effect of Oncotype DX Colon Cancer Test Results on Treatment Recommendations in Patients with Stage II Colon Cancer: Preliminary Results
Cartwright T, Chao C, Lopatin M, Bentley T, Broder M, Chang E
2012;

Top

2012 ASCO - Chicago, IL.

Abstract #e11002
Evaluation of variables that may impact the use of Oncotype DX testing.
Szabo S, Gilmore J, Haislip S, Hassell R, Cooper J, Richardson S, Fitzgerald M, Feinberg B; Georgia Cancer Specialists PC, Atlanta, GA; Cardinal Health, Specialty Solutions, Dublin, OH; Genomic Health, Redwood City, CA
2012;

Abstract #e11006
Can Oncotype DX recurrence score (RS) be used in luminal A and luminal B breast cancer patients (pts) to predict the likely benefit of chemotherapy? A retrospective study in the Spanish population.
García-Estevez L, Contreras A, Calvo I, Abad M, Cruz J, Perea S, Suárez A, López-Ríos F, Hidalgo M; Centro Integral Oncológico Clara Campal, Madrid, Spain; Centro Médico Guerra Méndez, Valencia, Venezuela; Dpto. Medicina Preventiva y Salúd Pública, UAM, Madrid, Spain
2012;

Abstract #e11032
Evaluation of the Oncotype Dx recurrence score (RS) in hormone-positive ipsilateral breast tumor recurrences.
Wapnir I, Florero M; Stanford University, Stanford, CA
2012;

Abstract #1005
Correlation between the DCIS score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study.
Badve S, Gray R, Baehner F, Solin L, Butler S, Yoshizawa C, Shak S, Hughes L, Page D, Sledge G, Davidson N, Perez E, Ingle J, Wood W, Sparano J; Indiana University School of Medicine, Indianapolis, IN; Dana-Farber Cancer Institute, Boston, MA; Genomic Health, Redwood City, CA; Albert Einstein Medical Center, Philadelphia, PA; The Hope Center, Cartersville, GA; Vanderbilt University, Nashville, TN; Indiana University Simon Cancer Center, Indianapolis, IN; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Department of Surgery, Emory University, Atlanta, GA; Albert Einstein College of Medicine, Bronx, NY
2012;

Abstract #1021
10-year update of E2197: Phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high-risk LN- breast cancer and the comparison of the prognostic utility of the 21-gene recurrence score (RS) with clinicopathologic features.
Sparano J, O'Neill A, Gray R, Perez E, Shulman L, Martino S, Badve S, Baehner F, Childs B, Yoshizawa C, Rowley S, Davidson N, Shak S, Goldstein L; Albert Einstein College of Medicine, Bronx, NY; Dana-Farber Cancer Institute, Boston, MA; Mayo Clinic, Jacksonville, FL; The Angeles Clinic and Research Institute, Santa Monica, CA; Indiana University School of Medicine, Indianapolis, IN; University of California, San Francisco, San Francisco, CA; Sanofi, Bridgewater, NJ; Genomic Health, Redwood City, CA; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Fox Chase Cancer Center, Philadelphia, PA
2012;

Abstract #1525
Cost-effectiveness of the 21-gene recurrence score assay in the setting of multifactorial decision making for chemotherapy in early-stage breast cancer.
Reed S, Dinan M, Schulman K, Lyman G; Duke Clinical Research Institute, Durham, NC; Duke University, Durham, NC
2012;

Abstract #3512
Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU+Ox)
O'Connell M, Lee M, Lopatin M, Yothers G, Clark-Langone L, Millward C, Paik S, Sharif S, Shak S, Wolmark N; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Genomic Health, Redwood City, CA; NSABP Biostatistical Center and University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA; National Surgical Adjuvant Breast and Bowel Project and Allegheny General Hospital, Pittsburgh, PA; National Surgical Adjuvant Breast and Bowel Project and Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, PA
2012;

Abstract #3626
Effect of the 12-gene colon cancer assay results on treatment recommendations in patients with stage II colon cancer
Cartwright T, Chao C, Lopatin M, Bentley T, Broder M, Chang E; Ocala Oncology, Ocala, FL; Genomic Health, Redwood City, CA; Partnership for Health Analytic Research, LLC, Beverly Hills, CA
2012;

Abstract #549
A prospective clinical utility study of the impact of the 21-gene recurrence score assay (Oncotype DX) in estrogen receptor positive (ER+) node negative (pN0) breast cancer in academic Canadian centers.
Davidson J, Cromwell I, Ellard S, Lohrisch C, Gelmon K, Shenkier T, Villa D, Lim H, Sun S, Taylor S, Taylor M, Czerkawski B, Hayes M, Ionescu D, Pope J, Berube J, Yoshizawa C, Chao C, Peacock S, Chia S; British Columbia Cancer Agency (Fraser Valley Centre), Surrey, BC, Canada; Canadian Centre for Applied Research in Cancer Control, Vancouver, BC, Canada; British Columbia Cancer Agency (Centre for the Southern Interior), Kelowna, BC, Canada; British Columbia Cancer Agency (Vancouver Centre), Vancouver, BC, Canada; Department of Pathology, British Columbia Cancer Agency (Vancouver Centre), Vancouver, BC, Canada; Genomic Health, Redwood City, CA; British Columbia Cancer Research Center, Vancouver, BC, Canada
2012;

Abstract #552
Prospective comparison of recurrence score and independent central pathology assessment of prognostic tools in early breast cancer (BC): Focus on HER2, ER, PR, Ki-67 results from the phase III WSG-Plan B trial.
Gluz O, Kreipe H, Christgen M, Degenhardt T, Kates R, Liedtke C, Shak S, Clemens M, Salem M, Markmann S, Liedtke B, Aktas B, Henschen S, Pollmanns A, Krabisch P, Uleer C, Augustin D, Thomssen C, Nitz U, Harbeck N; West German Study Group; West German Study Group, Moenchengladbach, Germany; Hannover Medical School, Hannover, Germany; University Hospital Munich, Cologne, Germany; REK Consulting, Otterfing, Germany; University of Muenster, Muenster, Germany; Genomic Health, Redwood City, CA; Klinikum Mutterhaus, Trier, Germany; University Clinics of Cologne, Cologne, Germany; University Clinic of Rostock, Rostock, Germany; Evangelical Hospital, Bergisch Gladbach, Germany; Department of Gynecology and Obstetrics, University of Duisburg-Essen, Essen, Germany; Johanniter Clinics Stendal, Stendal, Germany; EKO, Oberhausen, Germany; Department of Gynecology and Obstetrics, Klinikum Chemnitz, Chemnitz, Germany; Gynecology Practice, Hildesheim, Germany; Klinikum Deggendorf, Deggendorf, Germany; Martin Luther University Halle, Halle, Germany; West German Study Group and Evangelical Hospital Bethesda, Moenchengladbach, Germany; West German Study Group and University of Munich, Munich, Germany
2012;

Abstract #555
Obesity at diagnosis and breast cancer (BC) recurrence risk based on the 21-gene assay recurrence score (RS).
Ridolfi K, Zhang C, Onitilo A, Ledesma W, Andreason M, Engel K, Kim K, Wisinski K, Tevaarwerk A, Charlson J; Medical College of Wisconsin, Milwaukee, WI; University of Wisconsin Carbone Cancer Center, Madison, WI; Marshfield Clinic, Weston, WI
2012;

Abstract #563
Impact of exogenous female hormone use (EHU) on breast cancer (BC) recurrence as assessed by the 21-gene assay (Oncotype DX).
Ledesma W, Onitilo A, Zhang C, Kim K, Andreason M, Charlson J, Ridolfi K, Engel J, Wisinski K, Millholland R, Dean J, Tevaarwerk A; University of Wisconsin Carbone Cancer Center, Madison, WI; Marshfield Clinic, Weston, WI; Medical College of Wisconsin, Milwaukee, WI; University of Wisconsin Hospital and Clinics Cancer Registries, Madison, WI; University of Wisconsin, Madison, WI
2012;

Abstract #568
Prospective study of the impact of using the 21-gene recurrence score assay on clinical decision making in women with estrogen receptor-positive, HER2-negative, early-stage breast cancer in France.
Gligorov J, Pivot X, Naman H, Jacot W, Spaeth D, Misset JL, Largillier R, Sautiere JL, Roquancourt A, Pomel C, Rouanet P, Rouzier R, Penault-Llorca F; Francilian Breast Intergroup; APHP Tenon APREC, CancerEst, University Paris VI, Paris, France; University Hospital of Besancon, Besancon, France; Centre Azureen Cancerologie, Mougins, France; Centre Valdorel, Montpellier, France; Centre D'Oncologie De Gentilly, Gentilly, France; Hospital Saint Louis, Paris, France; Centre Azuréen de Cancérologie, Mougins, France; CHU Besançon, Besançon, France; APHP Hôpital Saint-Louis, Paris, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Val d'Aurellle, Montpellier, France; Tenon, Paris, France
2012;

Abstract #569
Evaluation of Oncotype DX testing and subsequent patterns of care in patients (pts) with early-stage breast cancer (ESBC).
Fitzgerald M, Hassell R, Haislip S, Gilmore J, Richardson S, Cooper J, Szabo S, Feinberg B; Cardinal Health, Specialty Solutions, Dublin, OH; Georgia Cancer Specialists PC, Atlanta, GA; Genomic Health, Redwood City, CA
2012;

Abstract #571
Evaluation of variables that may impact chemotherapy (CT) administration after determination of Oncotype DX (ODX) recurrence score (RS).
Bowen K, Gilmore J, Szabo S, Haislip S, Hassell R, Cooper J, Richardson S, Fitzgerald M, Feinberg B; Georgia Cancer Specialists PC, Atlanta, GA; Cardinal Health, Specialty Solutions, Dublin, OH; Genomic Health, Redwood City, CA
2012;

Abstract #6063
Rural versus urban differences among patients (pts) with hormone-receptor positive (HR+) breast cancer (BC) and a 21-gene assay recurrence score (RS).
Andreason M, Zhang C, Onitilo A, Charlson J, Ledesma A, Ridolfi K, Kim K, Wisinski K, Champeny T, Engel J, Millholland R, Dean J, Tevaarwerk A; University of Wisconsin, Madison, WI; Biostatistics, University of Wisconsin, Madison, WI; Marshfield Clinic, Weston, WI; Medical College of Wisconsin, Milwaukee, WI; University of Wisconsin Carbone Cancer Center, Madison, WI; University of Wisconsin Hospital and Clinics Cancer Registries, Madison, WI
2012;

Abstract #6098
Relationship between Oncotype DX testing and the use of chemotherapy in high-risk patients (pts).
Wong W, Cooper J, Richardson S, Feinberg B; CareFirst BlueCross BlueShield, Baltimore, MD; Cardinal Health, Specialty Solutions, Dublin, OH; Genomic Health, Redwood City, CA
2012;

Top

2012 Advances in Genome Biology and Technology Conference - Marco Island, Florida

Abstract #327
Prognostic Biomarker Discovery using RNA-Seq in Two Cohorts of Breast Cancer Patients
D. Sinicropi, M.-L. Liu, J. Stephans, M. Pho, J.Jeong, A. Scott, R. Ambannavar, J. Morlan, R. Pelham, K. Qu, F. Collin, J. Baker
2012;

Top

2011 SABCS - San Antonio, TX

Abstract #OD06-02
Cost-Effectiveness Evaluation of the Oncotype DX Breast Cancer Assay in Clinical Practice in the UK
Holt SDH, Bennett H, Bertelli G, Valentine WJ, Phillips CJ. Prince Philip Hospital, Llanelli, United Kingdom; Cardiff Research Consortium, Cardiff, United Kingdom; Singleton Hospital, Swansea, United Kingdom; Ossian Health Economics and Communications, Basel, Switzerland; Swansea University, Swansea, United Kingdom.
2011;

Abstract #P1-07-11
Consistency and Control in Clinical Assay Technology over Time: The Oncotype DX Recurrence Score and Assessment of Single Gene Expression Levels
Baehner FL, Butler SM, Anderson JM, Ballard J, Tan V, Shak S. Genomic Health, Inc., Redwood City, CA; UCSF, San Francisco, CA.
2011;

Abstract #P1-07-22
A Venezuelan Study of Breast Cancer Estrogen Receptor, Progesterone Receptor and HER2 Receptor Expression by the Standard Method, Immunohistochemistry (IHC), Compared to a New Method, Quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Marin C-EM, Ramirez AC, Baehner FL, Yoshizawa C, Acosta MM. Fundacion BADAN, Caracas, Miranda, Venezuela; Genomic Health, Redwood City, CA.
2011;

Abstract #P1-10-04
Cost-Utility of the 21-Gene Breast Cancer Assay (Oncotype DX) in the Irish Healthcare Setting
Lacey L, Chien R, Hornberger J. Lacey Solutions Ltd, South Strand, Skerries, County Dublin, Ireland; Cedar Associates LLC, Menlo Park, CA; Columbia University, New York, NY; Stanford University, Stanford, CA.
2011;

Abstract #P1-10-05
Is the 21-Gene Breast Cancer Test (Oncotype DX) Cost-Effective?
Pronzato P, Plun-Favreau J. Istituto Naz.le Ricerca Cancro, Genova, Italy; Genomic Health International Sàrl, Geneva, Switzerland.
2011;

Abstract #P1-10-06
Economic Analysis of Chemotherapy Costs for Adjuvant Therapy in Breast Cancer in France
Chereau E, Vataire A-L, Laas E, Genin A-S, Aballéa S, Rouzier R. Tenon - APHP, Paris, France; Creativ-Ceutical, Paris, France.
2011;

Abstract #P2-12-26
Impact of the Recurrence Score on Adjuvant Decision-Making in ER-Positive Early Breast Cancer - Results of a Large Prospective Multicentre Decision Impact Study in Node Negative and Node Positive Disease
Rezai M, Eiermann W, Kümmel S, Kühn T, Warm M, Friedrichs K, Schneeweiss A, Markmann S, Eggemann H, Hilfrich J, Jackisch C, Witzel I, Eidtmann H, Kaufmann M, Blohmer JU. Luisenkrankenhaus, Düsseldorf, Germany; Rotkreuzklinikum, München, Germany; Kliniken Essen-Mitte, Essen, Germany; Klinikum Esslingen, Esslingen, Germany; Krankenhaus Holweide, Köln, Germany; Brustzentrum, Hamburg, Germany; Universitätsklinikum, Heidelberg, Germany; Universitätsklinikum, Rostock, Germany; Universitätsklinikum, Magdeburg, Germany; Eilenriedeklinik, Hannover, Germany; Klinikum Offenbach, Offenbach, Germany; Universitätsklinikum Eppendorf, Hamburg, Germany; Universitätsklinikum, Kiel, Germany; Univesitätsklinikum, Frankfurt, Germany; Sankt Gertrauden-Krankenhaus, Berlin, Germany.
2011;

Abstract #P2-12-26
Comparison of Oncotype DX Recurrence Scores between Surgical and Core Biopsy Specimens in Breast Cancer Patients
Stull TS, Goodwin MC, Anderson JM, Baehner FL, Sing AP, Yoshizawa CN, Barrio AV, Frazier TG. The Bryn Mawr Hospital, Bryn Mawr, PA; Genomic Health, Inc, Redwood City, CA.
2011;

Abstract #P4-09-18
Australian Decision Impact Study: The Impact of Oncotype DX Recurrence Score (RS) on Adjuvant Treatment Decisions in Hormone Receptor Positive (HR+), Node Negative (N0) and Node Positive (N+) Early Stage Breast Cancer (ESBC) in the Multidisciplinary Clinic (MDC)
de Boer RH, Baker C, Speakman D, Mann B. Royal Melbourne Hospital, Melbourne, Victoria, Australia; Austin Hospital, Melbourne, Victoria, Australia; Peter MacCallum Cancer Institue, Melbourne, Victoria, Australia; Royal Melbourne and Royal Women's Hospital, Melbourne, Victoria, Australia.
2011;

Abstract #P5-13-09
Correlation of Oncotype DX Recurrence Scores with Pathologic Response Following Neoadjuvant Ixabepilone and Cyclophosphamide in Patients with HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial
Yardley DA, Peacock NW, Hendricks C, Huh SY, Ketchum S, Chao C, Yoshizawa C, Burris III HA, Hainsworth JD. Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; Center for Cancer and Blood Disorders, Bethesda, MD; Providence Medical Group, Terre Haute, IN; Mercy Hospital, Portland, ME; Genomic Health, Redwood City, CA.
2011;

Abstract #P5-14-03
Genomic Comparison of Paired Primary Breast Carcinomas and Macrometastatic Lymph Node Metastases Using Quantitative RT-PCR by Oncotype DX: Assessment of the Recurrence Score and Quantitative Single Genes
Boolbol SK, Kirstein L, Harshan M, Klein P, Cohen J-M, Chadha M, Baehner FL, Malamud SC. Beth Israel Medical Center, New York, NY; Genomic Health Inc., Redwood City, CA
2011;

Abstract #P5-14-26
Results from a Prospective Clinical Study on the Impact of Oncotype DX on Adjuvant Treatment Decision Making in a Cohort of 142 UK Patients
Holt S, Bertelli G, Brinkworth E, Durrani S, Jones S, Khawaja S, Laggner U, Moe M, Pudney D, Pitcher S, Rolles M, Sharaiha Y, Whelan S. Prince Philip Hospital, Llanelli, Carmarthenshire, United Kingdom; Singleton Hospital, Swansea, West Glamorgan, United Kingdom; Bronglais Hospital, Aberystwyth, Ceredigion, United Kingdom
2011;

Abstract #P5-18-03
First Interim Toxicity Analysis of the Randomized Phase III WSG Plan B Trial Comparing 4xEC-4xDoc Versus 6xTC in Breast Cancer Patients with HER2 Negative Breast Cancer (BC)
Nitz U, Gluz O, Krepe H, Liedtke B, Aktas B, Henschen S, Pollmanns A, Krabisch P, Zuna I, Shak S, Thomsseen C, Harbeck N. West German Study Group, Moenchengladbach, Germany; Breast Centre Niederrhein/Bethesda Hospital, Moenchengladbach, Germany; Bethesda Hospital, Wuppertal, Germany; Medizinishce Hochschule, Hannover, Germany; Evangelical Hospital, Bergisch Gladbach, Germany; University Hospital, Essen, Germany; Johanniter Hospital, Stendal, Germany; Evangelical Hospital, Oberhausen, Germany; City Hospital Chemnitz, Chemnitz, Germany; Genomic Health Inc, Redwood City, Germany; University Hospital Halle/Saale, Halle/Saale, Germany; University Hospital Cologne, Cologne, Germany.
2011;

Abstract #PD03-09
Breast Cancer Recurrence Risk Probed by Whole Transcriptome Next Generation Sequencing in 136 Patients
Baker J, Liu M-L, Crager M, Stephans J, Pho M, Jeong J, Scott A, Ambannavar R, Morlan J, Pelham R, Qu K, Mena RR, Esteban J, Collin F, Sinicropi D. Genomic Health Inc., Redwood City, CA; Providence St. Joseph Medical Center, Burbank, CA.
2011;

Abstract #S4-06
A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): A prospective validation study of the DCIS score from ECOG E5194
Solin LJ, Gray R, Baehner FL, Butler S, Badve S, Yoshizawa C, Shak S, Hughes L, Sledge G, Davidson N, Perez EA, Ingle J, Sparano JA, Wood W. Albert Einstein Medical Center, Philadelphia, PA; Eastern Cooperative Oncology Group, Boston, MA; Genomic Health, Inc., Redwood City, CA; Indiana University, Indianapolis, IN; The Hope Center, Cartersville, GA; University of Pittsburgh, Pittsburgh, PA; Mayo Clinic Jacksonville, Jacksonville, FL; Mayo Clinic Rochester, Rochester, MN; Albert Einstein College of Medicine, Bronx, NY; Emory University, Atlanta, GA.
2011;

Abstract #S4-3
Prospective comparison of risk assessment tools in early breast cancer (recurrence score, uPA/PAI-1, central grade, and luminal subtypes): Final correlation analysis from the phase III WSG-Plan B trial
Gluz O, Kreipe H, Degenhardt T, Kates R, Christgen M, Liedtke C, Shak S, Clemens M, Markmann S, Uleer C, Augustin D, Thomssen C, Nitz U, Harbeck N. West German Study Group, Moenchengladbach, Germany; Medizinische Hochschule, Hannover, Germany; University of Muenster, Muenster, Germany; Genomic Health Inc, Redwood City; Klinikum Mutterhaus, Trier, Germany; Klinikum Suedstadt, Rostock, Germany; Gynecology Practice, Hildesheim, Germany; Klinikum Deggendorf, Deggendorf, Germany; University of Halle/Saale, Halle/Saale, Germany; Bethesda Clinics, Moenchengladbach, Germany; University of Cologne, Cologne, Germany.
2011;

Top

2011 ASCO - Chicago, IL.

Abstract #558
A study of the Recurrence Score by the 21-gene signature assay as a predictor of clinical response to neoadjuvant exemestane for 24 weeks in estrogen-receptor-positive breast cancer.
N. Masuda, M. Toi, T. Ueno, T. Yamanaka, S. Saji, K. Kuroi, N. Sato, H. Takei, Y. Yamamoto, S. Ohno, H. Yamashita, K. Hisamatsu, K. Aogi, H. Iwata, S. Saji, H. Sasano; National Hospital Organization Osaka National
2011;

Abstract #592
Using the 21-gene Recurrence Score and the recently developed Recurrence Score-Clinical-Pathologic to assess recurrence risk in patients with node-negative, ER-positive early-stage breast cancer receiving aromatase inhibitor treatment alone.
M. Crager, G. Tang, S. Shak; Genomic Health, Redwood City, CA; NSABBP Biostatistical Center and University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA
2011;

Abstract #625
Evaluating utilization characteristics for the Oncotype DX Recurrence Score in early-stage breast cancer.
C. Chen, D. A. Patt, D. R. Kazzaz, J. Shankleton, M. T. Forsyth, R. Ganesh; US Oncology Healthcare Informatics, The Woodlands, TX; US Oncology, The Woodlands, TX; US Oncology Inc., The Woodlands, TX; US Oncology Inc., Houston, TX
2011;

Abstract #632
Evaluation of Recurrence Score and traditional clinicopathologic assessments in a large ER-positive, lymph node-negative patient cohort.
N. Liebermann, F. L. Baehner, L. Soussan-Gutman, S. Klang, C. Yoshizawa, S. Shak, N. Siegelmann-Danieli; Clalit Health Services, Tel Aviv, Israel; University of California, San Francisco, San Francisco, CA; Teva Pharmaceutical Industries, Netanya, Israel; Genomic Health, Redwood City, CA; Maccabi Health Organization, Tel Aviv, Israel
2011;

Abstract #1066
Ixabepilone and cyclophosphamide as neoadjuvant therapy in HER2-negative breast cancer with exploratory Oncotype DX assessments: A Sarah Cannon Research Institute phase II trial.
N. W. Peacock, D. A. Yardley, C. B. Hendricks, S. Y. Huh, S. L. Ketchum, C. Chao, C. Yoshizawa, M. Shastry, B. Strike, H. A. Burris, J. D. Hainsworth; Tennessee Oncology, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN; National Capital Clinical Research Consortium, Bethesda, MD; Coleman Cancer Center, Terre Haute, IN; Mercy Hospital, Portland, ME; Genomic Health, Redwood City, CA
2011;

Abstract #3518
Validation of a 12-gene colon cancer recurrence score (RS) in patients (pts) with stage II colon cancer (CC) from CALGB 9581.
A. P. Venook, D. Niedzwiecki, M. Lopatin, M. Lee, P. N. Friedman, W. Frankel, K. Clark-Langone, C. Yoshizawa, C. Millward, S. Shak, R. M. Goldberg, N. N. Mahmoud, R. L. Schilsky, M. M. Bertagnolli, Cancer and Leukemia Group B; University of California, San Francisco, San Francisco, CA; Duke University, Durham, NC; Genomic Health, Redwood City, CA; Cancer and Leukemia Group B, Chicago, IL; The Ohio State University, Columbus, OH; University of North Carolina at Chapel Hill, Chapel Hill, NC; University of Pennsylvania, Philadelphia, PA; The University of Chicago, Chicago, IL; Brigham and Women's Hospital, Boston, MA
2011;

Abstract #4541
Use of TMPRSS2-ERGgene rearrangement and quantitative ERG expression to predict clinical recurrence after radical prostatectomy.
S. M. Falzarano, C. Magi-Galluzzi, W. F. Novotny, T. Maddala, D. B. Cherbavaz, C. Millward and E. A. Klein Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Genomic Health, Redwood City, CA; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH
2011;

Abstract #4663
Quantitative gene expression in primary and highest Gleason pattern cancer specimens identifies genes associated with clinical recurrence and prostate cancer–specific survival after radical prostatectomy.
E. A. Klein, S. M. Falzarano, T. Maddala, M. Lee, R. J. Pelham, W. F. Novotny, S. Shak and C. Magi-Galluzzi Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH; Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Genomic Health, Redwood City, CA
2011;

Abstract #6111
A cost benefit analysis of the 21-gene breast cancer assay within a Canadian health care system.
S. Hassan, N. Mittmann; HOPE Research Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
2011;

Abstract #10594
Prospective comparison of Recurrence Score, uPA/PAI-1, central grade and molecular classification in early breast cancer: Interim results from the WSG-Plan B trial.
T. Degenhardt, O. Gluz, H. H. Kreipe, R. E. Kates, C. Liedtke, S. Shak, M. R. Clemens, D. Augustin, U. Nitz, N. Harbeck, on behalf of the Plan B investigators; University Hospital Cologne, Cologne, Germany; West German Study Group and Evangelical Hospital Bethesda, Wuppertal, Germany; Hannover Medical School, Hannover, Germany; REK Consulting, Otterfing, Germany; West German Study Group and University of Muenster, Muenster, Germany; Genomic Health, Redwood City, CA; Klinikum Mutterhaus, Trier, Germany; Klinikum Deggendorf, Deggendorf, Germany; West German Study Group and Evangelical Hospital Bethesda, Moenchengladbach, Germany; West German Study Group and University of Cologne, Cologne, Germany
2011;

Abstract #e10005
Evaluation of relation between Oncotype DX Recurrence Score and adjuvant chemotherapy administration.
D. R. Kazzaz, C. Chen, J. Shankleton, M. T. Forsyth, R. Ganesh, M. Sims, D. A. Patt; US Oncology Inc., The Woodlands, TX; US Oncology Healthcare Informatics, The Woodlands, TX; US Oncology Inc., Houston, TX; University of Texas, Austin, TX; US Oncology, The Woodlands, TX
2011;

Top

2011 Advances in Genome Biology and Technology Conference - Marco Island, Florida

Abstract # 198
Biomarker Discovery from Whole Transcriptome Analysis of Formalin-Fixed, Paraffin-Embedded Tumor and Normal Breast Specimens
Dominick Sinicropi, Kunbin Qu, John Morlan, Carl Millward, Francois Collin, James Stephans, Mei-Lan Liu, Mylan Pho, Jennie Jeong, Ranjana Ambannavar, Aaron Scott, and Joffre Baker
2011;

Top

2011 AACR Annual Meeting - Orlando, Florida

Transcriptome Profiling from Formalin-Fixed, Paraffin-Embedded Tumor Specimens by RNA-Seq
Kunbin Qu*, John Morlan, Jim Stephans, Xitong Li, Joffre Baker, Dominick Sinicropi
2010; From Beyond the Genome: The true gene count, human evolution and disease genomics:Boston, MA, USA. 11-13 October 2010.

Top

2011 SG-BCC - 12th International St.Gallen Breast Cancer Conference St.Gallen, Switzerland

Abstract #P196
Results from a prospective clinical study on the impact of Oncotype DX on adjuvant treatment decision and risk classification by Nottingham prognostic index (NPI) and recurrence score (RS)
S.D.H. Holt G. Bertelli, D. Pudney, M. Rolles, M. Moe, E. Brinkworth, S. Wheelan, S. Khawaja, S. Pitcher, Y. Sharaiha Breast Surgery, Prince Philip Hospital, Llanelli, Oncology Department, Singleton Hospital, Swansea United Kingdom
2011;

Abstract #P197
Oncotype Dx; St. Gallen risk group and Adjuvant!online nomogram as prognostic predictor for lymph nodes positive breast cancer patients
L. Leitzin N. Sikorsky, M. Leviov, E. Grikstass, M. Steiner Oncology Department, Lynn Medical Center, Haifa Israel
2011;

Abstract #P198
Prospective trans-GEICAM study of the impact of the 21-gene recurrence score assay and traditional clinico-pathological factors on clinical decision making in women with estrogen receptor-positive, HER2-negative, node-negative breast cancerand transGEICAM 2010-01 study investigators
J. Albanell R. Colomer, M. Ruiz-Borrego, E. Alba, J.A. García Saenz, M. Martin, I. Tusquets, F. Rojo, I. Faull, A. Lluch Hospital del Mar, Barcelona, MD Anderson, Madrid, Hospital Virgen del Rocío, Sevilla, Hospital Clínico, Málaga, Hospital Clínico, Hospital Gregorio Marañ
2011;

Abstract #P200
Impact of the 21-gene recurrence score assay on treatment decision in early breast cancer (EBC) patients with favourable prognostic factors
C. Markopoulos Athens University Medical School, Athens Greece
2011;

Abstract #P201
Meta-analysis of the decision impact of the 21-gene breast cancer Recurrence Score® in clinical practice
J.C. Hornberger R. Chien School of Medicine, Stanford University, Stanford, Cedar Associates LLC, Menlo Park United States
2011;

Abstract #P206
German multicentre decision impact study of Oncotype DX recurrence score (RS) on adjuvant treatment in estrogen receptor positive (ER+) node negative (N0) and node positive (N+) early breast cancer
J.U. Blohmer T. Kühn, M. Rezai, S. Kümmel, M. Warm, H. Eggemann, K. Friedrichs, W. Eiermann St. Gertraudenkrankenhaus, Berlin, Klinikum, Esslingen, Luisenkrankenhaus, Düsseldorf, Kliniken Essen Mitte, Essen, Krankenhaus Holweide, Köln, Universitätskrankenhaus, Magdebu
2011;

Abstract #P209
Evaluating conventional pathological factors against the standardized 21-gene signature for hormone receptor positive breast cancer patients
T. Onoda H. Yamauchi, H. Yagata, K. Tsugawa, K. Suzuki, S. Nakamura Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Breast Surgery, Yokohama Asahi Central General Hospital, Breast and Endocrine Surgery, St. Marianna School of Medicine, Kanagawa, Pa
2011;

Abstract #P215A
Cost-benefit analysis of a 21-gene recurrence score for early stage breast cancer in Singapore
G. de Lima Lopes R. Chien, J.C. Hornberger Medical Oncology, International Medical Centre Singapore, Singapore Singapore; Cedar Associates LLC, Menlo Park, School of Medicine, Stanford University, Stanford United States
2011;

Abstract #P215B
Evaluation of the cost-effectiveness of Oncotype-DX® multigene assay in Hungary
B. Madaras P. Rózsa, Z. Gerencsér, T. Radovics, I. Láng, Z. Nagy, Z. Horváth Chemotherapy B and Clinical Pharmacology, National Institute of Oncology, MediConcept Kft, Semmelweis Medical University, Faculty of Medicine, Med Gen-Sol Kft, Budapest Hungary
2011;

Top

2011 United States and Canadian Academy of Pathology Annual Meeting (USCAP), San Antonio, TX

Falzarano et al, Abstract #803
Prostate Cancer Gene Expression Adds Prognostic Information beyond Criteria such as Stage, Gleason Score, PSA, AUA Criteria, and CAPRA Score
SM Falzarano, C Magi-Galluzzi1,, T Maddala, D Cherbavaz, F Baehner, C Millward and EA Klein
2011;

Top

2011 American Society of Clinical Oncology, Genitourinary Cancers Symposium (ASCO GU), Orlando, FL

Abstract #39
Quantitative Gene Expression in Primary and Highest Gleason Pattern Cancers Identifies Genes Associated with Clinical Recurrence After Radical Prostatectomy
Klein EA, Falzarano SM,Maddala T,Millward C, Novotny WF,Pelham RJ,Cherbavaz D,Magi-Galluzzi C
2011;

Abstract #36
Neither TMPRSS2-ERG Gene Rearrangement nor Quantitative ERG Expression Predict Clinical Recurrence After Radical Prostatectomy
Klein EA,Falzarano SM, Maddala T, Cherbavaz D,Novotny WF,Millward C,Magi-Galluzzi
2011;

Top

2010 Society for Urologic Oncology (SUO) Annual Meeting - Bethesda, Maryland

Poster Session
Identification of Genes Associated with Clinical Recurrence in Men with Localized Prostate Cancer Treated with Radical Prostatectomy
Klein E,1Maddala T,2Falzarano S,3Cherbavaz D,2Novotny W,2Millward C,2Magi-Galluzzi C11Cleveland Clinic, Cleveland OH; 2Genomic Health, Inc., Redwood City, CA.
2010;

Top

2010 SABCS - San Antonio, TX.

Abstract #S4-9
Comparing the prediction of chemotherapy benefit in patients with node-negative, ER-positive breast cancer using the recurrence score and a new measure that integrates clinical and pathologic factors with the recurrence score
Tang G, Costantino JP, Crager M, Shak S, Wolmark N. NSABP, Pittsburgh, PA, Genomic Health Inc., Redwood City, CA.
2010;

Abstract #P2-09-06
Meta-Analysis of the Decision Impact of the 21-Gene Breast Cancer Recurrence Score in Clinical Practice
Hornberger J, Chien R. Stanford University, CA; Cedar Associates LLC, Menlo Park, CA.
2010;

Abstract #P3-10-01
Quantitative Gene Expression Analysis in a Large Cohort of Estrogen-Receptor Positive Breast Cancers: Characterization of the Tumor Profiles in Younger Patients (<= 40 yrs) and in Older Patients (>= 70 yrs)
Shak S, Baehner FL, Stein M, Chen I, Yoshizawa C, Watson D, Swain SM. Genomic Health, Inc, Redwood City, CA; Young Survival Coalition, New York, NY; Washington Hospital Center, Washington DC.
2010;

Abstract #P3-10-12
Pilot Phase of the Randomized PlanB Trial: Prospective Comparison of Molecular Classification, Oncotype DX® and Clinical-Pathological Characteristics in Hormone-Receptor (HR) Positive Primary Breast Cancer
Gluz O, Kreipe H, Christgen M, Salem M, Clemens M, Markmann S, Liedtke B, Barinoff J, Aktas B, Henschen S, Lübbe K, Shak S, Baehner R, Liedtke C, Nitz U, Harbeck N, on Behalf of the WSG/AGO Plan B Investigators. West German Study Group/Bethesda Wuppertal, Moenchengladbach, Germany; University of Hannover, Germany; University of Cologne, Dept. OB&GYN, Breast Centre, Germany; Klinikum Mutterhaus der Borromaeerinnen, Trier, Germany; University Hospital Rostock, Germany; Ev. Hospital, Bergisch Gladbach, Germany; Dr. Horst-Schmidt Hospital, Wiesbaden, Germany; University Hospital Essen, Germany; Johanniter Hospital, Stendal, Germany; University Hospital Muenster, Germany; Hospital Henriettenstiftung, Dept. OB&GYN, Hannover, Germany; Breast Center Niederrhein, Bethesda Hospital, Moenchengladbach, Germany; Genomic Health, Inc., Redwood City.
2010;

Abstract #P3-10-13
Prognostic Value of Genomic Analysis after Neoadjuvant Chemotherapy for Breast Cancer
Mayer EL, Shak S, Miller K, Rugo H, Carey L, Ryabin N, Pomeroy C, Yoshizawa C, Winer EP, Burstein HJ. Dana-Farber Cancer Institute, Boston, MA; Genomic Health, Inc, Redwood City, CA; Indiana University Simon Cancer Center, Indianapolis; University of California San Francisco, Helen Diller Family Comprehensive Cancer Center; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill.
2010;

Abstract #P3-10-15
Quantitative Gene Expression by RT-PCR in Classic and Variant Forms of Lobular Carcinoma in Estrogen Receptor Positive Invasive Breast Cancer
Anderson JM, Yoshizawa C, Winer EP, Watson D, Millward C, Tan V, Shak S, Baehner FL. Genomic Health, Redwood City, CA; Dana-Farber Cancer Institute, Boston, MA; University of California, San Francisco.
2010;

Top

2010 ASCO - Chicago, IL.

Abstract #509
Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach.
G. Tang, J. Cuzick, C. Wale, J. P. Costantino, M. Crager, S. Shak, N. Wolmark, M. Dowsett, J. F. Forbes; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Queen Mary, University of London, London, United Kingdom; Genomic Health, Redwood City, CA; National Surgical Adjuvant Breast and Bowel Project and Allegheny General Hospital, Pittsburgh, PA; The Royal Marsden Hospital, London, United Kingdom; University of Newcastle, Newcastle-upon-Tyne, United Kingdom

Abstract #511
Potential biologic causes of the racial survival disparity in adjuvant trials of ER-positive breast cancer.
K. S. Albain, W. E. Barlow, S. Shak, G. N. Hortobagyi, D. F. Hayes, for The Breast Cancer Intergroup of North America; Loyola University Medical Center, Maywood, IL; Cancer Research and Biostatistics, Seattle, WA; Genomic Health, Redwood City, CA; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Michigan Medical Center, Ann Arbor, MI

Abstract #6075
The recurrence score and chemotherapy treatment in node-positive, ER+ early-stage breast cancer patients in Israel.
S. Klang, N. Liebermann, S. Rizel, N. Ben-Baruch, S. Merling, L. Soussan-Gutman, R. Bugarini, C. Chao, S. Shak; Clalit Health Services, Tel Aviv, Israel; Rabin Medical Center, Petah Tikva, Israel; Kaplan Medical Center, Rehovot, Israel; Teva Pharmaceutical Industries, Netanya, Israel; Genomic Health, Redwood City, CA

Abstract #e11077
Effect of 21-gene recurrence score results on treatment recommendations in patients age 65 and older with lymph node-positive, estrogen receptor-positive breast cancer.
R. Oratz, C. Chao, S. Skrzypczak, C. Ory, M. Broder; New York University School of Medicine, New York, NY; Genomic Health, Redwood City, CA; Partnership for Health Analytic Research, Beverly Hills, CA

Abstract #4501
Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC).
B. I. Rini, M. Zhou, H. Aydin, P. Elson, T. Maddala, D. Knezevic, L. Parodi, R. M. Bukowski, W. F. Novotny, J. W. Cowens; Cleveland Clinic, Cleveland, OH; Genomic Health, Redwood City, CA; Pfizer, Inc., New York, NY; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Abstract #3503
Comparison of molecular and pathologic features of stage II and stage III colon cancer in four large studies conducted for development of the 12-gene colon cancer recurrence score.
M. J. O'Connell, I. C. Lavery, R. G. Gray, P. Quirke, D. J. Kerr, M. Lopatin, G. A. Yothers, M. Lee, K. Clark-Langone, N. Wolmark; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Cleveland Clinic Foundation, Cleveland, OH; University of Birmingham, Birmingham, United Kingdom; University of Leeds, Leeds, United Kingdom; Sidra Medical and Research Center, Doha, Qatar; Genomic Health, Redwood City, CA; National Surgical Adjuvant Breast and Bowel Project Biostatistical Center and University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA; National Surgical Adjuvant Breast and Bowel Project and Allegheny General Hospital, Pittsburgh, PA

Abstract #3097
Association of vorinostat with decrease in gene expression of proliferation-related genes in tumors from women with newly diagnosed breast cancer.
V. Stearns, L. K. Jacobs, T. N. Tsangaris, Z. Cheng, S. Slater, M. J. Fackler, C. Chao, R. Bugarini, E. Gabrielson, N.E. Davidson; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Johns Hopkins School of Medicine, Baltimore, MD; Anne Arundel Medical Center, Annapolis, MD; Genomic Health, Redwood City, CA; University of Pittsburgh Cancer Institute, and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA

Top

2010 Advances in Genome Biology and Technology Conference - Marco Island, Florida

Abstract # 170
Transcriptome Profiling from Formalin-Fixed, Paraffin-Embedded Tumor Specimens by RNA-Seq
D Sinicropi, G Schroth, Shujun Luo, I Khrebtukova, J Baker, X Li, K Qu, J Morlan
2010;

Top

2010 AACR Annual Meeting – Washington, DC

Abstract #2160
New prognostic breast cancer biomarkers selected from formalin fixed tissue RNA samples after whole transcriptome amplification.
M. Cronin, M. Liu, J. Jeong, A. Scott, R. Ambannavar, M. Pho, H. Son, M. Kiefer, F. Collin, J. Baker, Genomic Health, Inc., Redwood City, CA
2010;

Top

2009 United States and Canadian Academy of Pathology (USCAP) Annual Meeting Boston, MA

Abstract # 1421
HER2 Concordance between Central Laboratory Immunohistochemistry, FISH and Quantitative RT-PCR in Intergroup Trial E2197
Baehner FL, Gray R, Maddala T, Childs B, Rowley S, Shak S, Davidson NE, Sledge GW, Goldstein LJ, Sparano JA, Badve S
2009;

Abstract # 1574
Biopsy Cavities in Breast Cancer Specimens: Impact on Quantitative RT-PCR Gene Expression Profiles and Recurrence Risk Assessment
FL Baehner, C Quale, C Pomeroy, D Cherbavaz, S Shak.
2009;

Abstract # 2285
ER and PR Assessment by Central IHC: Examination and Comparison of Percent Positive Cells and Nuclear Staining Intensity in ECOG Breast Cancer Study 2197
S Badve, R Gray, B Childs, T Maddala, M Liu, S Rowley, N Davidson, S Shak, LJ Goldstein, GW Sledge, JA Sparano, FL Baehner
2009;

Top

2009 SABCS---San Antonio, TX

Abstract #112
Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer – An Update of SWOG-8814 (INT0100).
Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh I-T, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne
2009;

Abstract #2031
Effect of 21-Gene Recurrence Score Results on Treatment Recommendations in Patients with Lymph Node-Positive, Estrogen Receptor-Positive Breast Cancer
Oratz R, Chao C, Skrzypczak S, Kim B, Broder M New York University School of Medicine, New York, NY; Genomic Health, Inc., Redwood City, CA; David Geffen School of Medicine at UCLA, Los Angeles, CA; Pardee RAND Graduate School, RAND Corporation, Santa Monica, CA; Partnership for Health Analytic Research, Beverly Hills, CA
2009;

Abstract #5165
Gene Expression Profiling of Phenotypically-Defined Hormone-Receptor Positive Breast Cancer: Evidence for Increased Transcriptional Activity of the Insulin Growth Factor Receptor Pathway and Other Pathways.
Sparano JA, Gray R, Goldstein LJ, Childs BH, Brassard D, Bugarini R, Rowley S, Baker J, Shak S, Badve S, Baehner FL, Kenny P, Perez EA, Shulman LN, Martino S, Sledge GW, Davidson NE Eastern Cooperative Oncology Group, Brookline, MA; Sanofi-Aventis, Inc., Bridgewater, NJ; Genomic Health, Inc., Redwood City, CA; North Central Cancer Treatment Group, Rochester, MN; Cancer and Leukemia Group B, Chicago, IL; Southwest Oncology Group, Ann Arbor, MI
2009;

Abstract #6004
HER2 Amplification, Polysomy Status and Breast Cancer Survival in a Large Kaiser Permanente Case-Control Study: Assessment of HER2 by Quantitative Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and Fluorescence In
Baehner FL, Achacoso N, Maddala T, Alexander C, Shak S, Quesenberry CP, Habel LA University of California, San Francisco, San Francisco, CA; Kaiser Permanente Northern
2009;

Abstract #6021
Molecular Characterization of Breast Cancer Core Biopsy Specimens by Gene Expression Analysis Using Standardized Quantitative RT-PCR.
Anderson JM, Shak S, Millward C, Labusch M, Chen I, Watson D, Baehner FL Genomic Health, Inc., Redwood City, CA

Top

2009 Kyoto Breast Cancer Consensus Conference International Convention―Kyoto, Japan

Abstract
The First Report Of The Association Between The Recurrence Score And The Risk Of Recurrence In A Japanese Population
M. Toi, H. Iwata, N. Masuda, S. Ohno, S. Namakura, Y.Yamanaka, T. Nakayama, M. Kashiwaba, S, Kamigaki, K. Aogi, T. Ueno, K. Kuroi.
2009;

Top

2009 ASCO Breast Meeting - San Francisco, CA

Abstract # 64
Biopsy Cavities in Breast Cancer Specimens: Their Impact on Quantitative RT-PCR Gene Expression Profiles and Recurrence Risk Assessment
FL Baehner, C. Quale, D. Cherbavaz, C. Sangli, C. Pomeroy, A. Chen, F. Lane, L. Intagliatta, A. Goddard, S. Shak; University of California, San Francisco, Redwood City, CA; Genomic Health, Redwood City, CA
2009;

Top

2009 ASCO Annual Meeting― Orlando, FL

Abstract # 500
Genotypic characterization of phenotypically defined triple-negative breast cancer
J. A. Sparano, L. J. Goldestin, B. H. Childs, S. Shak, S. Badve, F. L. Baehner
2009;

Abstract # 549
Molecular characterization of male breast cancer by standardized quantitative RTPCR analysis: First large genomic study of 347 male breast cancers compared to 82,434 female breast cancers.
S. Shak, G. Palmer, F. L. Baehner, C. Millward, D. Watson, G. W. Sledge
2009;

ASCO 2009 Abstract #4000
A quantitative multi-gene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in 4 large studies and results of the independent, prospectively-designed QUASAR validation study
D. Kerr, R. Gray, P. Quirke, D. Watson, G. Yothers, I. C. Lavery, M. Lee, M. J. O'Connell, S. Shak, N. Wolmark and the Genomic Health & QUASAR Colon Teams; University of Oxford, Oxford, UK; Birmingham Clinical Trials Unit, Birmingham, UK; Leeds Institute of Molecular Medicine, Leeds, UK; Genomic Health, Inc., Redwood City, CA; NSABP, Pittsburgh, PA; Cleveland Clinic Foundation (CCF), Cleveland, OH; Genomic Health, Inc., Redwood City, CA; NSABP, Pittsburgh, PA; Genomic Health, Inc., Redwood City, CA; NSABP, Pittsburgh, PA
2009;

Top

2008 United States and Canadian Academy of Pathology (USCAP) Annual Meeting―Denver, CO

Abstract #82 : Oral Presentation
Analysis of Revised Nottingham Tumor Grade Constitutive Components and Recurrence Free Interval in ECOG Breast Cancer Study E2197
FL Baehner, LJ Goldstein, R Gray, T Maddala, S Shak, GW Sledge, JA Sparano, S Badve
2008;

Abstract #44 : Poster Session
Comparison of ER and PR Assessment by Local IHC, Central IHC, and Central Quantitative RT-PCR in ECOG Breast Cancer Study 2197
S Badve, FL Baehner, R Gray, B Childs, T Maddala, M Liu, S Rowley, N Davidson, LJ Goldstein, GW Sledge, JA Sparano
2008;

Abstract #47 : Poster Session
A Kaiser-Permanente Population-Based Study of Breast Cancer ER and PR Expression by the Standard Method, Immunohistochemistry, Compared to a New Method, Quantitative Reverse Transcription Polymerase Chain Reaction
FL Baehner, T Maddala, C Alexander, A Gown, LC Goldstein, y, S Shak, CP Quesenberry, L Habel
2008;

Abstract #50 : Poster Session
Heterogeneity of Quantitative RT-PCR Measurement of Estrogen and Progesterone Receptor Expression: Comparison of Tissue Microarray Cores to Whole Sections of Paraffin Embedded Breast Cancer Tissue
FL Baehner, J Baker, J Salter, ML Liu, C Yoshizawa, T Maddala, M Dowsett, M Cronin, S Shak
2008;

Top

2008 San Antonio Breast Cancer Symposium (SABCS)-San Antonio, TX

Abstract # 25
GRB7-dependent pathways are potential therapeutic targets in triple-negative
Sparano JA, Gray R, Goldstein LJ, Childs BH, Bugarini R, Rowley S, Baker J, Shak S,
2008;

Abstract # 53
Risk of distant recurrence using Oncotype DX in postmenopausal primary breast
Dowsett M, Cuzick J, Wales C, Forbes J, Mallon L, Salter J, Quinn E, Bugarini R,
2008;

Abstract # 2066
Quantitative gene expression analysis using Oncotype DX in ductal carcinoma in
Baehner FL, Sangli C, Millward C, Cherbavaz D, Goddard A, Shak S Genomic Health,Inc, Redwood City, CA
2008;

Abstract # 3049
Associations between estrogen receptor (ER) Alpha expression levels and ER genotypes
Henry NL, Shak S, Banerjee M, Skaar T, Palmer G, Braman M, Stearns V,Flockhart DA, Kleer C, Hayes DF, Rae J University of Michigan, Ann Arbor, MI; Genomic Health,Inc., Redwood City, CA; Indiana University, Indianapolis, IN; Johns Hopkins University,Baltimore, MD
2008;

Top

2008 Hematology/Oncology Pharmacy Association (HOPA)—Anaheim, CA

Abstract #2601: Poster Session
Low Recurrence Score by the Oncotype DX Breast Cancer Assay Rarely Results in Recommendation for or Administration of Chemotherapy: A Pooled Analysis
P Hall, S Skrzypczak, G Palmer
2008;

Top

2008 ASCO Gastrointestinal Cancers Symposium—Orlando, FL

Abstract #301 : Poster Session
Relationship Between Tumor Gene Expression and Recurrence in Patients with Stage II/III Colon Cancer Treated with Surgery + 5-FU/LV in NSABP C-06: Consistency of Results with Two Other Independent Studies
MJ O'Connell, G Yothers, S Paik, IC Lavery, JW Cowens, KM Clark-Langone, MLopatin, JR Hackett, FL Baehner, N Wolmark

Abstract #302 : Poster Session
Relationship Between Tumor Gene Expression and Recurrence in an Observational Cohort of Patients with Stage II/III Colon Cancer Treated with Surgery Only: Quantitative RT-PCR Assay of 375 Genes in Fixed Paraffin-Embedded (FPE) Tissue
I Lavery, J Hammel, J Cowens, K Clark-Langone, J Hackett, F Baehner, G Yothers, M OConnell, N Wolmark

Top

2008 ASCO Annual Meeting―Chicago, IL

Abstract #557
Predictive Utility of Progesterone Receptor (PR) and Multigene Expression in Identifying Benefit From Adjuvant Doxorubicin Plus Cyclophosphamide (AC) or Docetaxel (AT) in Intergroup Trial E2197
LJ Goldstein, RJ Gray, R Bugarini, S Shak, SS Badve, FL Baehner, NE Davidson, GW Sledge, JA Sparano, The North American Breast Cancer Intergroup
2008;

Abstract #3512
Evaluation of Tumor Gene Expression and K-Ras Mutations in FFPE Tumor Tissue as Predictors of Response to Cetuximab in Metastatic Colorectal Cancer
JB Baker, D Dutta, D Watson, T Maddala, S Shak, EK Rowinsky, L Xu, E Clark, DJ Mauro, S Khambata-Ford

Top

2008 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium—Washington DC

Abstract #13
HER2 Concordance Between Central Laboratory Immunohistochemistry & Quantitative Reverse Transcription Polymerase Chain Reaction in Intergroup Trial E2197
FL Baehner, R Gray, B Childs, T Maddala, S Rowley, S Shak, NE Davidson, GW Sledge, LJ Goldstein, JA Sparano, S Badve
2008;

Abstract #41
HER2 Assessment in a Large Kaiser Permanente Case-Control Study: Comparison of Fluorescence In Situ Hybridization (FISH) and Quantitative Reverse Transcription Polymerase Chain Reaction (RTPCR) Performed by Central Laboratories
FL Baehner, Achacoso, T Maddala, C Alexander, S Shak, CP Quesenberry, LC Goldstein, AM Gown, LA Habel
2008;

Top

2007 San Antonio Breast Cancer Symposium (SABCS)―San Antonio, TX

Abstract #10 : Oral Presentation
Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal, Node-Positive, ER-Positive Breast Cancer
K Albain, W Barlow, S Shak, G Hortobagyi, R Livingston, I Yeh, P Ravdin, C Yoshizawa, FL Baehner, N Davidson, G Sledge, E Winer, C Hudis, J Ingle, E Perez, K Pritchard, L Shepherd, C Allred, K Osborne, D Hayes
2007;

Abstract #63 : Oral Presentation
Prognostic Utility of the 21-Gene Assay Compared with Adjuvant! in Hormone Receptor (HR) Positive Operable Breast Cancer with 0-3 Positive Axillary Nodes Treated with Adjuvant Chemohormonal Therapy (CHT): An Analysis of Intergroup Trial E2197
L Goldstein, P Ravdin, R Gray, C Yoshizawa, B Childs, S Rowley, S Shak, S Badve, FL Baehner, N Davidson, GW Sledge, JA Sparano

Abstract #1043 : Poster Session
Recurrence Score by Oncotype DX Evaluated on the Primary Breast Predicts the 2-Year Survival after First Relapse
G Bianchini, M Zambetti, P Mariani, A Moliterni, G Bianchi, G Mariani, A Fasolo, ML Carcangiu, P Valagussa, L Gianni
2007;

Abstract #1092 : Poster Session
Prospective Multi-Center Study of the Impact of the 21-Gene Recurrence Score Assay on Patient Satisfaction, Anxiety and Decisional Conflict for Adjuvant Breast Cancer Treatment Selection
PB Mumby, SS Lo, J Norton, J Smerage, K Joseph, HK Chew, D Hayes, KS Albain

Abstract #2061 : Poster Session
A Retrospective Analysis of the Impact of Oncotype DX Low Recurrence Score Results on Treatment Decisions in a Single Academic Breast Cancer Center
H Liang, AM Brufsky, BB Lembersky, P Rastogi, VG Vogel
2007;

Abstract #3028 : Poster Session
Gene Expression by Standardized Quantitative RT-PCR in the Special Histologic Subtypes of Estrogen Receptor-Positive Invasive Breast Cancer
FL Baehner, D Watson, JT Ballard, G Palmer, S Shak
2007;

Abstract #3082 : Poster Session
Evaluation of Practice Patterns in the Treatment of Node-Negative, Hormone-Receptor Positive Breast Cancer Patients with the Use of the Oncotype DX Assay at the University of Pennsylvania
C Erb, KR Fox, M Patel, K Hook, A DeMichele, C Kaplan, S Domchek
2007;

Abstract #5029 : Poster Session
Estrogen Receptor and Breast Cancer Survival in a Kaiser Permanente Population-Based Study: Comparison of Quantitative Reverse Transcriptase Polymerase Chain Reaction and Immunohistochemistry
LA Habel, N Achacoso, T Maddala, C Alexander, FL Baehner, S Shak, C Quesenberry, AM Gown, LC Goldstein
2007;

Top

2007 ASCO Breast Cancer Symposium―San Francisco, CA

Abstract #27
Association of Individual Genes with Risk of Relapse in Operable Breast Cancer: Analysis of E2197
JA Sparano, L Goldstein, B Childs, C Yoshizawa, S Shak, J Baker, S Rowley, N Davidson, S Badve, GW Sledge Jr., R Gray
2007;

Abstract #87
ER and PR Assessment in ECOG 2197: Comparison of Locally Determined IHC with Centrally Determined IHC and Quantitative RT-PCR
SS Badve, FL Baehner, R Gray, B Childs, T Maddala, M Liu, S Rowley, N Davidson, S Shak, GW Sledge Jr., JA Sparano
2007;

Abstract #88
A Kaiser-Permanente Population-Based Study of ER and PR Expression by the Standard Method, Immunohistochemistry (IHC), Compared to a New Method, Quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR)
FL Baehner, T Maddala, C Alexander, A Gown, LC Goldstein, NS Achacoso, S Shak, CP Quesenberry, LA Habel
2007;

Abstract #106
Use of Estrogen Receptor (ER) Expression by Quantitative RT-PCR to Identify an ER-Negative Subgroup by IHC Who Might Benefit from Hormonal Therapy
G Bianchini, M Zambetti, L Pusztai, M Carcangiu, P Valagussa, L Gianni
2007;

Top

2007 ASCO Annual Meeting―Chicago, IL

Abstract #526 : Poster Discussion
Prognostic Utility of the 21-Gene Assay in Hormone Receptor (HR)-Positive Operable Breast Cancer and 0-3 Positive Axillary Nodes Treated with Adjuvant Chemohormonal Therapy (CHT): An Analysis of Intergroup Trial E2197
LJ Goldstein, R Gray, B Childs, D Watson, S Rowley, S Shak, S Badve, NE Davidson, GW Sledge, JA Sparano
2007;

Abstract #577 : Poster Session
Prospective Multi-Center Study of the Impact of the 21-Gene Recurrence Score (RS) Assay on Medical Oncologist (MO) and Patient (PT) Adjuvant Breast Cancer (BC) Treatment Selection
SS Lo, J Norton, PB Mumby, J Smerage, J Kash, HK Chew, D Hayes, A Epstein, KS Albain
2007;

Top

2007 American Association for Cancer Research (AACR) Annual Meeting―Los Angeles, CA

Abstract #4423 : Poster Session
Optimized RNA Extraction and RT-PCR Provide Successful Molecular Analysis on a Variety of Archival Fixed Tissues
M Zhou, M Bronner, C Magi-Galluzzi, R Tuthill, FL Baehner, ML Liu, D Dutta, J Jeong, YT Chen, JR Hackett, M Cronin
2007;

Top

2006 SABCS―San Antonio, TX

Abstract #45 : Oral Presentation
Quantitative RT-PCR Analysis of ER and PR by Oncotype DX Indicates Distinct and Different Associations with Prognosis and Prediction of Tamoxifen Benefit
FL Baehner, LA Habel, CP Quesenberry, A Capra, G Tang, S Paik, N Wolmark, D Watson, S Shak
2006;

Abstract #3116 : Poster Presentation
A Comparison of Estrogen Receptor (ER) Measurement by Three Methods in Node-Negative, Estrogen Receptor (ER)-Positive Breast Cancer: Ligand Binding (LB), Immunohistochemistry (IHC), and Quantitative RT-PCR
C Kim, G Tang, FL Baehner, D Watson, JP Costantino, S Paik, S Shak, N Wolmark
2006;

Abstract #6039 : Poster Presentation
The Impact on the Recurrence Score Due to Patient Variation in the Quantitative Expression of Individual Genes or Gene Groups
D Watson, G Palmer, J Baker, S Shak
2006;

Abstract #6111 : Poster Presentation
Relationship Between Proliferation Genes and Expression of Hormone and Growth Factor Receptors: Quantitative RT-PCR in 10,618 Breast Cancers
S Shak, FL Baehner, G Palmer, JT Ballard, J Baker, D Watson
2006;

Abstract #6118 : Poster Presentation
Subtypes of Breast Cancer Defined by Standardized Quantitative RT-PCR Analysis of 10,618 Tumors
S Shak, FL Baehner, G Palmer, JT Ballard, J Baker, D Watson
2006;

Top

2006 Association for Molecular Pathology (AMP) Annual Meeting―Orlando, FL

Poster ST23 : Poster ST23
Analytical Validation for the Oncotype DX Breast Cancer Assay, High Complexity, Multi-Analyte Molecular Diagnostic Test Service
M Cronin, C Sangli, ML Liu, M Pho, D Dutta, A Nguyen, J Jeong, J Wu, K Clark, D Watson
2006;

Top

2006 ASCO Annual Meeting―Atlanta, GA

Abstract #538 : Poster Discussion
Gene Expression Profiles in Formalin-Fixed, Paraffin-Embedded (FFPE) Core Biopsies Predict Docetaxel Chemosensitivity
JC Chang, A Makris, SG Hilsenbeck, JR Hackett, J Jeong, ML Liu, J Baker, K Sexton, CK Osborne, S Shak
2006;

Abstract #6024 : Poster Discussion
21-Gene RT-PCR Assay in Lymph Node-Negative (LN-), Estrogen Receptor-Positive (ER+) Breast Cancer: An Economic Analysis Including Prognostic and Predictive Information
LE Cosler, NM Kuderer, J Hornberger, GH Lyman
2006;

Abstract #3518 : Poster Discussion
Relationship Between Tumor Gene Expression and Recurrence in Stage II/III Colon Cancer: Quantitative RT-PCR Assay of 757 Genes in Fixed Paraffin-Embedded (FPE) Tissue
MJ O’Connell, S Paik, G Yothers, JP Costantino, JW Cowens, KM Clark, J Baker, J Hackett, D Watson, N Wolmark

Top

2006 AACR Annual Meeting―Washington, DC

Abstract #3604 : Poster Discussion
Multiple GSTM Gene Family Members Are Recurrence Risk Markers in Breast Cancer
M Kiefer, K Hoyt, J Hackett, MG Walker, J Baker
2006;

Top

2005 SABCS―San Antonio, TX

Abstract #29 : Oral Presentation
Association Between the 21-Gene Recurrence Score Assay (RS) and Risk of Loco-Regional Failure in Node-Negative, ER-Positive Breast Cancer: Results from NSABP B-14 and NSABP B-20
E Mamounas, G Tang, J Bryant, S Paik, S Shak, JP Costantino, D Watson, DL Wickerham, N Wolmark
2005;

Abstract #310 : Poster Discussion
Measurement of Gene Expression Using Tissue Microarray Cores of Paraffin-Embedded Breast Cancer Tissue
J Baker, J Salter, ML Liu, JR Hackett, M Cronin, S Shak, M Dowsett
2005;

Abstract #2049 : Poster Session
Impact of Oncotype DX™ on Decision Making in Breast Cancer Clinical Practice
R Oratz, D Paul, A Cohn, S Sedlacek
2005;

Top

2005 ASCO Annual Meeting―Orlando, FL

Abstract #510 : Oral Presentation
Expression of the 21 Genes in the Recurrence Score Assay and Tamoxifen Clinical Benefit in the NSABP Study B-14 of Node-Negative, Estrogen Receptor-Positive Breast Cancer
S Paik, S Shak, G Tang, C Kim, J Baker, M Cronin, D Watson, J Bryant, JP Costantino, N Wolmark
2005;

Abstract #603 : Poster Session
Gene Expression and Breast Cancer Mortality in Northern California Kaiser Permanente Patients: A Large Population-Based Case Control Study
LA Habel, CP Quesenberry, M Jacobs, D Greenberg, L Fehrenbacher, C Alexander, J Baker, D Watson, J Hackett, S Shak
2005;

Top

2004 USCAP Annual Meeting―Vancouver, British Columbia

Abstract #83 : Oral Presentation
Comparison of ER, PR, HER2, and Ki-67 Quantitative Expression in Formalin-Fixed, Paraffin-Embedded Breast Carcinomas by RT-PCR with Protein Expression by Immunohistochemistry
P Bitterman, D Watson, M Cronin, JM Mosquera, M Cobleigh, R Baehner, S Shak, J Baker
2004;

Abstract #80
Use of Macrodissection in Multi-Gene RNA Analysis of Fixed Paraffin- Embedded Tumor Tissue
R Baehner, B Hiller, CY Kim, C Alexander, ML Liu, M Pho, D Dutta, J Jeong, A Nguyen, M Walker, M Cronin, J Baker, S Paik
2004;

Abstract #1491
Reproducibility of Quantitative Gene Expression Analysis by a New RT-PCR Assay Using Fixed Paraffin-Embedded Tissues: A Molecular Tomographic Scanning Study
M Cronin, D Watson, D Dutta, ML Liu, M Pho, R Baehner, J Esteban, J Baker, S Shak
2004;

Top

2004 SABCS―San Antonio, TX

Abstract #24 : Oral Presentation
Expression of the 21 Genes in the Recurrence Score Assay and Prediction of Clinical Benefit from Tamoxifen in NSABP Study B-14 and Chemotherapy in NSABP Study B-20
S Paik, S Shak, G Tang, C Kim, H Joo, J Baker, M Cronin, D Watson, J Bryant, JP Costantino, N Wolmark
2004;

Abstract #104 : Poster Discussion
Risk Classification of Breast Cancer Patients by the Recurrence Score Assay: Comparison to Guidelines Based on Patient Age, Tumor Size, and Tumor Grade
S Paik, S Shak, G Tang, C Kim, J Baker, M Cronin, FL Baehner, MG Walker, D Watson, J Bryant, N Wolmark
2004;

Abstract #2081 : Poster Discussion
A 21-Gene RT-PCR Assay in Lymph Node-Negative (LN-), Estrogen Receptor-Positive (ER+) Early-Stage Breast Cancer (ESBC): An Age-Specific Economic Analysis
GH Lyman, L Cosler, J Hornberger
2004;

Top

2004 ASCO Annual Meeting―New Orleans, LA

Abstract #501 : Oral Presentation
Gene Expression Profiles of Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Patients with Locally Advanced Breast Cancer
L Gianni, M Zambetti, K Clark, J Baker, M Cronin, G Mariani, J Rodriguez, M Carcangiu, D Watson, P Valagussa, S Shak
2004;

Abstract #6036 : Poster Session
Economic Analysis of Targeting Chemotherapy (CT) Using a 21-Gene RT-PCR Assay in Lymph Node-Negative (LN-), Estrogen Receptor-Positive (ER+) Early-Stage Breast Cancer (ESBC)
LE Cosler, J Hornberger, GH Lyman
2004;

Top

2003 SABCS―San Antonio, TX

Abstract #16 : Oral Presentation
Multi-Gene RT-PCR Assay for Predicting Recurrence in Node-Negative Breast Cancer Patients - NSABP Studies B-20 and B-14
S Paik, S Shak, G Tang, C Kim, J Baker, M Cronin, FL Baehner, MG Walker, DWatson, T Park, W Hiller, ER Fisher, DL Wickerham, J Bryant, N Wolmark
2003;

Abstract #17 : Oral Presentation
Prognostic Role of a Multigene Reverse Transcriptase-PCR Assay in Patients with Node-Negative Breast Cancer Not Receiving Adjuvant Systemic Therapy
FJ Esteva, AA Sahin, M Cristofanilli, K Coombes, SJ Lee, J Baker, M Cronin, MG Walker, D Watson, S Shak, GN Hortobagyi
2003;

Top

2003 ASCO Annual Meeting―Chicago, IL

Abstract #3415 : Poster Session
Tumor Gene Expression Predicts Distant Disease-Free Survival (DDFS) in Breast Cancer Patients with 10 or More Positive Nodes: High Throughput RT-PCR Assay of Paraffin-Embedded Tumor Tissues
MA Cobleigh, P Bitterman, J Baker, M Cronin, ML Liu, R Borchik, B Tabesh, J Mosquera, MG Walker, S Shak
2003;

Abstract #3416 : Poster Discussion
Tumor Gene Expression and Prognosis in Breast Cancer: Multi-Gene RT-PCR Assay of Paraffin-Embedded Tissue
JM Esteban, J Baker, M Cronin, ML Liu, MG Llamas, MG Walker, R Mena, S Shak
2003;

Abstract #3466 : Poster Session
Predicting Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer: Gene Expression Profiling of Paraffin-Embedded Core Biopsy Tissue
SE Soule, S Shak, J Baker, M Cronin, ML Liu, S Badve, KD Miller, GW Sledge
2003;

Abstract #763 : Oral Presentation
Quantitative Gene Expression in Non-Small Cell Lung Cancer from Paraffin-Embedded Tissue Specimens: Predicting Response to Gefitinib, an EGFR Kinase Inhibitor
RB Natale, S Shak, N Aronson, S Averbuch, W Fox, D Luthringer, K Clark, J Baker, M Cronin, DB Agus

Top

2003 AACR Oncogenomics Meeting―Phoenix, AZ

Poster Session
Strategies to Optimize Anti-Receptor Therapies
J Baselga

Poster Session : Poster Session
Gene Expression Profiling of Fixed, Paraffin-Embedded Tumor Specimens, Using a 192 Gene Panel RT-PCR Assay
M Kiefer, J Stephans, ML Liu, D Dutta, M Pho, A Nguyen, J Jeong, M Cronin, JM Esteban
2003;

Top

2002 ASCO Annual Meeting―Orlando, FL

Abstract #3017
Gene Expression Profiling of Fixed Paraffin-Embedded Breast Cancer Tissues
M Kiefer, J Stephans, S Abulaban, S Shodhan, MC Alexander, JM Esteban
2002;

Top